PROFNAIT: Collaborating To Combat Rare Disease
This article was originally published in Start Up
Prophylix Pharma is set to be the first company to begin clinical trials for a prophylactic for fetal and neonatal alloimmune thrombocytopenia, a rare but serious disorder that can cause serious bleeding in babies' brains. Its candidate, NAITgam, is being developed under the auspices of the PROFNAIT consortium, an innovative collaborative project involving 11 Northern European universities, hospitals, research organizations, companies, and blood banks.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.